Higher Stroke Rate in COVID-19 vs Influenza
New study provides further support for as well as more insight on stroke risk associated with COVID-19.
Related Articles
Heart of Cardio
earn up to 13.25 cme/ce credits At the 4th Annual Going Back to the Heart of Cardiology, we’ll explore the latest advancements in Cardiology, from…
ACC Conference Wrap-up: Thromboembolic Disease and Antithrombotic Therapy Highlights
Join us as our faculty review highlights from the conference and discuss optimal management of thromboembolic disease in 2024.
ACC Conference Wrap-up: Thromboembolic Disease Highlights
Join us for a symposium on thromboembolic disease designed to encourage the exchange of ideas between leaders in the field and attendees. Click the ‘Notify…
ACC Conference Wrap-up: Thromboembolic Disease Highlights
Join us for a symposium on thromboembolic disease designed to encourage the exchange of ideas between leaders in the field and attendees. Click the ‘Notify…
ACC Conference Wrap-up: Thromboembolic Disease Highlights
Join us for a symposium on thromboembolic disease designed to encourage the exchange of ideas between leaders in the field and attendees. Click the ‘Notify…
Home
Anticoagulant use has been critical for reducing the risk of stroke in patients with atrial fibrillation. However, currently available agents are often underutilized or utilized…
Home
Anticoagulant use has been critical for reducing the risk of stroke in patients with atrial fibrillation. However, currently available agents are often underutilized or utilized…
Who Benefits From Beta Blocker Withdrawal in HFpEF?
A new study suggested indexed left ventricular systolic volume may predict benefit of beta blocker withdrawal in patients with heart failure with preserved ejection fraction.
New Marker of Cardiovascular Risk Discovered in T2D
The quantity of dysfunctional monocytes appears to indicate poor cardiovascular prognosis in patients with type 2 diabetes, data suggested.
FDA Panel in Favor of TriClip for Tricuspid Regurgitation
An FDA advisory panel voted 13 to 1 that the benefits of Abbott’s first-of-its-kind transcatheter system to treat tricuspid regurgitation outweigh any potential risks.